Proteasome inhibition in multiple myeloma: lessons for other cancers

Area of Science:

• Biochemistry
• Cell Biology
• Oncology

Background:

• Cellular protein homeostasis relies on the ubiquitin-proteasome system (UPS) for protein degradation.
• The 26S proteasome is crucial for regulated proteolysis and cellular function.
• Proteasome inhibitors, initially research tools, are now key anticancer drugs for multiple myeloma (MM).

Purpose of the Study:

• To review the mechanisms of proteasome inhibitors' selective toxicity in MM cells.
• To discuss resistance mechanisms to proteasome inhibition.
• To explore broader applications of proteostasis-targeting drugs in cancer therapy.

Main Methods:

• Review of existing literature on proteasome inhibitors in multiple myeloma.
• Analysis of mechanisms including endoplasmic reticulum stress, amino acid depletion, and metabolic effects.
• Examination of resistance pathways like autophagy and metabolic rewiring.

Main Results:

• Proteasome inhibitors induce preferential toxicity in MM cells via ER stress, nutrient depletion, and metabolic disruption.
• Resistance can occur through adaptive mechanisms such as autophagy and metabolic reprogramming.
• Understanding these factors is crucial for optimizing proteasome inhibitor therapy.

Conclusions:

• Proteasome inhibitors are effective in MM by exploiting vulnerabilities in protein homeostasis.
• Mechanisms of resistance necessitate further research for improved therapeutic strategies.
• Lessons learned from MM may inform the development of proteostasis-targeting drugs for other malignancies.